Values First Advisors, Inc. Alnylam Pharmaceuticals, Inc. Transaction History
Values First Advisors, Inc.
- $177 Million
- Q2 2025
A detailed history of Values First Advisors, Inc. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Values First Advisors, Inc. holds 3,947 shares of ALNY stock, worth $1.8 Million. This represents 0.73% of its overall portfolio holdings.
Number of Shares
3,947
Previous 8,113
51.35%
Holding current value
$1.8 Million
Previous $2.19 Million
41.23%
% of portfolio
0.73%
Previous 1.32%
Shares
23 transactions
Others Institutions Holding ALNY
# of Institutions
744Shares Held
115MCall Options Held
584KPut Options Held
672K-
Capital World Investors Los Angeles, CA16.8MShares$7.67 Billion0.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$6.07 Billion0.07% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$4.36 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.19MShares$3.28 Billion0.49% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.28MShares$1.95 Billion0.88% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $56.1B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...